Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Anastrozole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 19/20 | 1.00 |
| ▸ | UGT1A4 | P22310 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | STS | P08842 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anastrozole SCHEMBL9726 | 1.00 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL27927481 | 1.00 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL28771766 | 0.99 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL5917785 | 0.99 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL3172308 | 0.99 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL10324455 | 0.96 | CYP19A1 (0.92) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL13323739 | 0.95 | CYP19A1 (0.90) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL8059026 | 0.93 | CYP19A1 (0.87) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL354747 | 0.92 | CYP19A1 (0.85) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL12908863 | 0.92 | CYP19A1 (0.85) | CYP19A1UGT1A4PDE4DESR1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1952 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105541-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LIGACHEM BIOSCIENCES INC. (KR) | 2015-04-16 | — | — | US | claimed |
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| US-12043667-B2 | CLEC12a binding polypeptides and uses thereof | INHIBRX BIOSCIENCES, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12037385-B2 | Anti-polyubiquitin antibodies and methods of use | GENENTECH, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240228664-A9 | Antibodies Binding to Human PAD4 and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226082-A1 | COMBINATION THERAPIES FOR TREATING CANCER | TESARO, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228653-A1 | PSGL-1 Antagonists and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024148315-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-12030947-B2 | Humanized and affinity matured antibodies to FcRH5 and methods of use | GENENTECH, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030926-B2 | Production of heteromultimeric proteins using mammalian cells | GENENTECH, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240200146-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH INC (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2005044853-A2 | ANTI-VEGF ANTIBODIES | GENENTECH, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050090514-A1 | Trp-p8 active compounds and therapeutic treatment methods | GENENTECH, INC. | 2005-04-28 | — | — | US | disclosed |
| WO-2005033132-A2 | IGF BINDING PROTEINS | GENENTECH, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050037431-A1 | Methods and compositions for modulating HGF/Met | GENENTECH, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2005012359-A2 | ANTI-VEGF ANTIBODIES | GENENTECH, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005003154-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| EP-1401476-A2 | IGF ANTAGONIST PEPTIDES | Genentech, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030092631-A1 | IGF antagonist peptides | GENENTECH, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002072780-A2 | IGF ANTAGONIST PEPTIDES | GENENTECH, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105541-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FCGRT, CD47, FNTA | CYP19A1 3331/4885UGT1A4 2149/4885PDE4D 3384/4885 |
| US-20050090514-A1 | Trp-p8 active compounds and therapeutic treatment methods | TSG101, TP53, BAX | CYP19A1 2235/4885UGT1A4 2830/4885PDE4D 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.